Send to

Choose Destination
Data Brief. 2018 Dec 19;22:557-562. doi: 10.1016/j.dib.2018.12.056. eCollection 2019 Feb.

Peptidome profiling dataset of ovarian cancer and non-cancer proximal fluids: Ascites and blood sera.

Author information

Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency of the Russian Federation, Malaya Pirogovskaya 1a, Moscow 119435, Russian Federation.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya str. 16/10, Moscow 117997, Russian Federation.
Moscow Institute of Physics and Technology (State University), Institutskii Per. 9, Moscow Region, Dolgoprudny 141700, Russian Federation.


Despite a large number of proteomic studies of biological fluids from ovarian cancer patients, there is a lack of sensitive screening methods in clinical practice (Kim et al., 2016) (DOI:[1]). Low molecular weight endogenous peptides more easily diffuse across endothelial barriers than proteins and can be more relevant biomarker candidates (Meo et al., 2016) (DOI:[2], (Bery et al., 2014) DOI:[3], (Huang et al., 2018) DOI:[4]). Detailed peptidomic analysis of 26 ovarian cancer and 15 non-cancer samples of biological fluids (ascites and sera) were performed using TripleTOF 5600+ mass-spectrometer. Prior to LC-MS/MS analysis, peptides were extracted from biological fluids using anion exchange sorbent with subsequent peptide desorption from the surface of highly abundant proteins. In total, we identified 4874 peptides; 3123 peptides were specific for the ovarian cancer samples. The mass-spectrometry peptidomics data presented in this data article have been deposited to the ProteomeXchange Consortium (Deutsch et al., 2017) (DOI:[5]) via the PRIDE partner repository with the dataset identifier PXD009382 and,

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center